m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study

R. D. Hilgers, S. S. Legha, F. J. Panettiere, D. S. Alberts

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Twenty-three patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with m-AMSA. Eleven patients received a mean of 2.3 courses at a dose of 40 mg/m2 x 3 days q 21 days and 12 patients received a mean of 4.3 courses at a dose of 30 mg/m2 x 3 days q 21 days intravenously. One (5%) partial response in 22 fully evaluable patients was observed. Toxicity was mild and well tolerated. We conclude that m-AMSA is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)277-279
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume6
Issue number3
DOIs
StatePublished - 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'm-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this